| U.S. Market Potential - Addressing A $400Bn Substance Abuse Problem(1)
Drug Screening Products Market Segment Size: $16.17Bn by 2030(2)
CAGR: 14%(2)
Market Drivers
- Stronger regulations and workplace safety focus
- Rising substance abuse rates
- Increased awareness of safety implications relating to drug use in high-risk industries
- Growing demand for fast, non-invasive testing
Opp.
- Meets demand for speed, accuracy, and convenience
- Set to replace traditional urine and saliva tests
Grab Sources And More: INBS Website. INBS Presentation. -----
And based on multiple potential catalysts mentioned above, (Nasdaq: INBS) has quickly risen the ranks to the top spot on my watchlist. Check them out:
#1. INBS Potential Catalyst - A Tiny Float Could Create Heightened Volatility In A Flash.
According to info from the Yahoo Finance website, INBS has a tiny low float.
In fact, the website reports this profile to have approx. 868.43k shares in its float.
Why is that important? It's important on one crucial level. Volatility potential.
If the company provides positive news towards the end of 2025, could it, with the help of a low float, help create a breakout spark? -----
#2. INBS Potential Catalyst - An Analyst $12 Target Suggests Triple-Digit Potential Upside.
From its closing valuation on Wednesday, that $12 target is suggesting INBS to have over 100% potential upside.
This price target reflects strong analyst confidence in Intelligent Bio Solutions Inc.'s future performance, driven by major advances in FDA regulatory pathways for its drug screening system and a strategic expansion into new markets including key partnerships in Europe and initiatives for a U.S. launch.
Ladenburg Thalmann's established reputation as a Wall Street firm adds further weight to the target and underscores the attention INBS could receive as an undervalued profile. -----
#3. INBS Potential Catalyst - The Company's Fiscal Q1 2026 Revenue Increases 32% Y-O-Y, Shows Growing Market Adoption.
Intelligent Bio Solutions Reports Fiscal 2026 First Quarter Financial Results and Operational Highlights, Delivering Record Revenue Growth
Record quarterly revenue of $1.11Mn, an increase of 32% sequentially and 28% year-over-year, driven by consumable cartridge sales and customer base expansion
Gross pro-fit margins increased 690 basis points year-over-year to 46.6%, reflecting improved operational efficiency and greater revenue percentage from higher margin cartridge sales
NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal first quarter ended September 30, 2025.
The fiscal 2026 first quarter delivered record quarterly revenue of $1.11Mn, driven by accelerating cartridge sales, significant customer acquisition, and strategic partnerships that position INBS for continued expansion across key international markets. The Company's consumable-focused business model demonstrated strong momentum, with cartridge sales representing nearly 58% of total revenue. Gross pro-fit margins increased by 690 basis points year-over-year to 46.6%, due to improved operational efficiency and a greater revenue percentage from higher margin cartridge sales.
"Our first quarter results show accelerating momentum of our business model and the growing market adoption internationally of our non-invasive drug screening technology," said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. "We achieved record quarterly revenue of $1.11Mn, representing our strongest quarter to date, with 32% growth sequentially and 28% year-over-year. This significant revenue increase, combined with expanding gross margins, validates our strategic focus on consumable cartridge sales and positions us well for sustained growth as we advance along the regulatory pathway toward planned FDA clearance and U.S. market entry."
...
Read the full article here. -----
#4. INBS Potential Catalyst - New Customers Accounts Keep Piling Up As Company Secures 33 More.
Intelligent Bio Solutions Secures 33 New Customer Accounts in the Fiscal 2026 First Quarter, Showing Strong Year-Over-Year Growth and Increasing Total Active Accounts to 480
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the addition of 33 new customer accounts during its fiscal first quarter for the period ended September 30, 2025, representing a 50% increase compared with the same period the prior year. The continued growth brings the Company’s total number of active accounts to over 480, demonstrating sustained customer expansion and revenue momentum.
Year-over-year analysis, based on full-year figures, highlights the strongest growth in customer acquisition within the maritime, transportation and logistics, electrical and electronic manufacturing, construction, and government administration sectors. Notably, government administration represents a newly entered sector, emphasizing the expanding applicability of INBS's solutions across both public and private domains where operational safety and compliance are critical.
"Our expanding customer base demonstrates increasing confidence in our technology and the growing recognition of its value proposition. As we move toward the second quarter of fiscal year 2026, our focus remains on converting this momentum into sustained revenue growth and long-term value," said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. "Our fingerprint-based drug testing technology is helping organizations streamline screening, minimize downtime, and enhance compliance, delivering measurable operational and economic benefits."
...
Read the full article here. -----
#5. INBS Potential Catalyst - A Major New UK Contract Gets Secured With A Multinational Industrial Service Provider.
Intelligent Bio Solutions Secures Major UK Contract with Multinational Industrial Service Provider
Multinational company employs approximately 3,000 staff within the UK and Ireland and more than 30,000 staff worldwide
Large new customer account highlights accelerating adoption of the Company's rapid, non-invasive drug testing technology across high-volume, safety-critical sectors
NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has secured a major new contract with one of the United Kingdom's largest industrial service providers.
The multinational company, a global leader operating across the energy, defence, nuclear, and industrial sectors, employs more than 30,000 people worldwide and services complex, safety-critical projects across Europe, the Middle East, and Asia-Pacific. Within the UK and Ireland, the company employs approximately 3,000 staff across multiple sites.
...
“Securing this account highlights the expanding market confidence in our technology and its growing role in transforming drug testing across some of the world's largest industrial operators,” said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. "Each new enterprise adoption validates our value proposition, strengthens our commercial trajectory, and expands recurring consumables revenue potential."
...
Read the full article here. -----
(Nasdaq: INBS) Recap - 5 Potential Catalysts Lead The Way
#1. A Low Float Could Create Heightened Volatility In A Flash.
#2. An Analyst $12 Target Suggests Triple-Digit Potential Upside.
#3. The Company's Fiscal Q1 2026 Revenue Increases 32% Y-O-Y, Shows Growing Market Adoption.
#4. New Customers Accounts Keep Piling Up As Company Secures 33 More.
#5. A Major New UK Contract Gets Secured With A Multinational Industrial Service Provider. -----
We're now reinitiating coverage on Intelligent Bio Solutions Inc. (Nasdaq: INBS).
As soon as updates pop up, I'll get them out quickly. Talk soon.
Sincerely, FierceAnalyst | Jaks Swift Editorial Writer
Sources: (1)(2)
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor ("FI") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 12/17/2025 and ending on 12/18/2025 to publicly disseminate information about (INBS:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid sixty thousand USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither SWN Media LLC, TD Media LLC and their member own shares of (INBS:US).
Please see important disclosure information here: https://fierceinvestor.com/disclosure/inbs-kxhqr/#details | 
Tidak ada komentar:
Posting Komentar